Abstract
18F-fluoride is a positronemitting bone-seeking agent, the uptake of which reflects blood flow and remodeling of bone. Taking advantage of the favorable pharmacokinetic properties of the tracer combined with the high performance of PET technology, 18F-fluoride PET is a highly sensitive imaging modality for detection of benign and malignant osseous abnormalities. 18Ffluoride not only detects osteoblastic lesions but also detects lytic and early marrow-based metastases, by identifying their accompanying reactive osteoblastic changes, even when minimal. The instant fusion of 18F-fluoride data with morphological data of CT using hybrid PET/CT systems improves the specificity of 18F-fluoride PET in cancer patients, accurately differentiating between benign and malignant sites of uptake. 18F-fluoride PET and PET/CT is, however, not widely used in clinical practice. The limited availability of 18F-fluoride PET and PET/CT systems is a major factor. However, it has been stated by some experts that 18F-fluoride PET/CTis expected to replace 99m-Tc-MDP bone scintigraphy or act as a solving problem technology in specific clinical scenarios.
| Translated title of the contribution | Role of positron emission tomography with fluorine 18 in the assessment of bony metastases |
|---|---|
| Original language | French |
| Pages (from-to) | 225-229 |
| Number of pages | 5 |
| Journal | Oncologie |
| Volume | 12 |
| Issue number | 3 |
| DOIs | |
| State | Published - Mar 2010 |
Keywords
- Bone metastasis
- Bone scintigraphy
- F18-Fluoride
- Osteoblastic lesions
- PET/CT
